Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues. The main doubts regarding the optimal selection of the patient are the role of this drug in first line of treatment, the individualization of the correct methodology of radiologic assessment and efficacy analysis, the best management of immune-mediated adverse events, and how to overcome the immunoresistance. The aim of this review is to analyze literature data on nivolumab in lung cancer with a focus on critical aspects related to the drug in terms of safety, the use in clinical practice, and possible placement in the treatment algorithm.

Cortinovis, D., Canova, S., Abbate, M., Colonese, F., Bidoli, P. (2016). Focus on nivolumab in NSCLC. FRONTIERS IN MEDICINE, 3(DEC), 67 [10.3389/fmed.2016.00067].

Focus on nivolumab in NSCLC

Cortinovis D. L.;Abbate M.;Bidoli P.
2016

Abstract

Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues. The main doubts regarding the optimal selection of the patient are the role of this drug in first line of treatment, the individualization of the correct methodology of radiologic assessment and efficacy analysis, the best management of immune-mediated adverse events, and how to overcome the immunoresistance. The aim of this review is to analyze literature data on nivolumab in lung cancer with a focus on critical aspects related to the drug in terms of safety, the use in clinical practice, and possible placement in the treatment algorithm.
Articolo in rivista - Articolo scientifico
Checkpoint inhibitors
Immunotherapy
Nivolumab
NSCLC
PD-1
PDL1
English
2016
3
DEC
67
67
open
Cortinovis, D., Canova, S., Abbate, M., Colonese, F., Bidoli, P. (2016). Focus on nivolumab in NSCLC. FRONTIERS IN MEDICINE, 3(DEC), 67 [10.3389/fmed.2016.00067].
File in questo prodotto:
File Dimensione Formato  
10281-281352.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 169.94 kB
Formato Adobe PDF
169.94 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/281352
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
Social impact